You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 131 No. 6, June 1977 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (42)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Prevention or Modification of Varicella Using Zoster Immune Plasma

Henry H. Balfour, Jr, MD; Karl E. Groth; Jeffrey McCullough, MD; Janal M. Kalis; Stephen C. Marker, MD; Mark E. Nesbit, MD; Richard L. Simmons, MD; John S. Najarian, MD

Am J Dis Child. 1977;131(6):693-696.


Abstract



• Zoster immune plasma (ZIP) was given to 31 susceptible immunocompromised children one to seven days (median, two days) following household, playmate, or hospital exposures to varicella. The average amount of ZIP transfused was 7 ml/kg. Twenty-one children did not develop varicella or persistent antibodies to varicella-zoster virus (VZV). Eight (26%) of the 31 contracted clinical varicella. Seven cases were mild, but in one child, who was given ZIP seven days after exposure, visceral disease developed and the child died. Two children had subclinical varicella that was documented by persistence of VZV antibodies for at least ten months after passive immunization. Because none of the 30 children given ZIP one to six days following exposure had severe varicella, we conclude that ZIP is effective in preventing or modifying varicella in immunocompromised patients if given shortly after exposure.

(Am J Dis Child 131:693-696, 1977)



Author Affiliations



From the Departments of Laboratory Medicine and Pathology, Surgery, and Pediatrics, University of Minnesota Health Sciences Center, Minneapolis.


Footnotes



Reprint requests to Box 437 Mayo, University of Minnesota Health Sciences Center, Minneapolis, MN 55455 (Dr Balfour).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Varicella-Zoster Antibody Titers in Children With Leukemia and Lymphoma: Relationship of Titer to Varicella-Zoster Infection
Hutter et al.
Arch Pediatr Adolesc Med 1984;138:56-59.
ABSTRACT  

Varicella in the Immunocompromised Host
Preblud et al.
JAMA 1978;239:2551-2552.
ABSTRACT  

Evaluation of Zoster Immune Plasma: Treatment of Cutaneous Disseminated Zoster in Immunocompromised Patients
Groth et al.
JAMA 1978;239:1877-1879.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.